BRAF and familial atrioventricular septal defect: The recent discovery that more than 60% of patients with ECD have the BRAFV600E mutation has led to the indication of targeted therapies (MEK and BRAF inhibitors).3, 4 However, when BRAF mutation is negative, there have not been prospective controlled therapeutic trials to compare treatments.